Eko Health Expands Clinical Advisory Board

Eko Health is expanding its Clinical Advisory Board to help the company transform the ways in which heart and lung disease are detected and managed. The board will provide strategic guidance on Eko’s clinical research and implementation strategy, inform product development, and help ensure the company’s work continues to advance equitable access to early disease detection.

The Clinical Advisory Board is chaired by Dr. Steve Steinhubl, a cardiologist and professor of biomedical engineering at Purdue University. Prior to Purdue, Dr. Steinhubl was director of Digital Medicine at the Scripps Translational Science Institute, where he led pioneering work in wearable health technologies and digital trials.

“Eko has transformed the stethoscope into a gateway for AI-powered disease detection,” Dr. Steinhubl said. “By unlocking clinical insights during routine exams, they’re shifting the paradigm for how and where cardiopulmonary disease is caught. This advisory board will help ensure those advancements reach the clinicians and patients who stand to benefit most.”

Expanded Clinical Advisory Board includes:

• Dr. Steve Steinhubl (chair): Cardiologist, clinical trialist, and professor of biomedical engineering at Purdue University.
• Dr. Ankeet Bhatt: Cardiologist and clinical investigator at Kaiser Permanente San Francisco Medical Center and Division of Research; adjunct professor at Stanford University School of Medicine.
• Dr. Antoine Keller: Cardiothoracic surgeon at Ochsner Lafayette General Hospital; co-founder and president of HeartSense.
• Dr. Joanna Kmiecik: Family medicine physician; Education-Centered Medical Home lead/preceptor at Northwestern University Feinberg School of Medicine, and medical director at Oak Street Health.
• Dr. Jennifer Kwan: Cardiologist and physician-scientist at Yale University; assistant professor of cardiovascular medicine specializing in cardiovascular imaging (MRI/CT), cardio-oncology, and multi-omics technologies.
• Dr. Lisa Rotenstein: Primary care physician at UCSF Health; director of the Center to Advance Digital Physician Practice Transformation, and assistant professor of medicine.
• Dr. James Thomas: Cardiologist; director of the Center for Heart Valve Disease, and professor of medicine at Northwestern University Feinberg School of Medicine.

“Our Clinical Advisory Board brings together leading voices across the healthcare continuum. These are physicians innovating in their own practices and pushing the boundaries of what’s possible with technology,” Eko Health Co-Founder/CEO Connor Landgraf stated. “As we advance AI-powered detection tools, their insights will help us build responsibly, scale effectively, and stay focused on improving patient care.”

This announcement follows a series of significant clinical milestones for Eko, including U.S. Food and Drug Administration (FDA) clearances for its low ejection fraction and structural murmur detection algorithms, the publication of peer-reviewed validation studies in Nature Medicine, The Lancet Digital Health and JACC: Advances, and the introduction of a new Category III CPT code effective July 1.

Eko Health is an AI early disease detection company advancing the ways in which healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes and ECG devices, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, with more than 650,000 devices sold to providers globally, allows them to detect earlier and with higher accuracy, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, Calif.